Elevara Medicines

Immunology & Inflammation Therapeutics · Biotechnology
1 public contract won
$39kPublic contracts won1 public contract
Data updated Nov 20, 2026Money ledger: 1 record from 1 sourceAnnounced 1Full reportReport a mistake
Lately:$39k won in the last 12 monthsFollow changes →

Facts

as of Nov 20, 2026

Elevara Medicines is a clinical-stage biotech. ELV001 targets fibroblast-like synoviocytes and synergizes with DMARDs to achieve clinical remission in RA.

Employees
51-200estimated range

These are the key facts about Elevara Medicines on Alion as of Nov 20, 2026. The latest round is Series A of $70M, announced in 2025.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Elevara Medicines has $70M paid in by investors, lenders and donors.

$70MPaid in
Money innewest first
Equity raised
Oct 2025 · Series A
$70MPaid
Money by yearUSD, rounds and grants
2025$70M1 record
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Products

1 public contract won, $39k in all. $39k of it in the last 12 months.

Biggest buyers1 · $39k
Fakultní nemocnice v Motole
Czech Republic · 1 public contract
$39k
Milestones
Raised a round Series A $70M
Oct 21, 2025
Jan 2011
Sources: the outlets named on each headline, each story once

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices